ICON Survey Reveals Sustained Investment in AI for Clinical Research, Despite Challenges in Widespread Adoption

ICON's Global Survey on AI and Digital Innovation in Clinical Research

ICON plc, a leading clinical research organization, has released the results of a global survey examining the adoption of AI and digital innovation in clinical research. The survey, conducted among 101 biotech and pharma professionals across Europe and North America, provides insights into the current state and future trajectory of AI implementation in the industry 1

1

2

2

.

Sustained Optimism and Investment in AI

The survey reveals a continued positive outlook on the potential impact of AI and digital tools in clinical research. Compared to a similar survey conducted in 2019, sponsors' optimism about AI's potential to improve R&D productivity has grown by 5% 1

1

. Key findings include:

• 82% of respondents believe digital tools can improve return on R&D investments
• 76% agree that these tools can enhance product safety and efficacy
• 76% see AI as supporting their ability to compete in targeted medicine markets 1

  1

  2

  2

Investment in AI and digital tools remains significant, with an average total investment increase of 34% over the past five years. Looking ahead, 88% of respondents expect their organizations to increase investment in the next one to two years 1

1

.

Challenges in Large-Scale Adoption

Despite the optimism and investment, the survey highlights challenges in widespread adoption of AI in clinical development:

• 70% of respondents are either piloting or selectively using AI in clinical development
• Only 13% report having a comprehensive AI program fully implemented 1

  1

  2

  2

The primary concerns delaying broader digital adoption include:

1. Patient safety
2. Data integrity
3. Regulatory compliance 1

   1

Realistic Expectations and Strategic Approaches

Tom O'Leary, Chief Information Officer at ICON, notes that the industry has gained a greater appreciation of the investment required to capitalize on AI and digital tools over the last five years 1

1

. He emphasizes the need for companies to embrace these tools at a broad level, rather than in one-off applications, to fully realize productivity gains 2

2

.

ICON's Recommendations

To address the challenges and maximize the benefits of AI in clinical research, ICON recommends:

1. Taking a more integrated approach to digital tools and AI
2. Implementing comprehensive and strategic approaches to navigate complexity
3. Utilizing tools designed specifically for clinical trials to address unique challenges and regulatory demands 1

   1

   2

   2

ICON has released a whitepaper, "Digital disruption: Surveying the industry's evolving landscape," which provides guidance on addressing barriers in complex trials and avoiding operational disruptions associated with digital transformation 1

1

.

Industry Implications

The survey results indicate a maturing perspective on AI adoption in clinical research. While investment and optimism remain high, there is a more measured approach to implementation, with companies recognizing the complexities and regulatory challenges involved. This shift suggests a move towards more strategic and comprehensive AI integration in the biotech and pharmaceutical industries 1

1

2

2

.